View in EDS HTML Full Text PDF Full Text

Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.

Saved in:
Bibliographic Details
Title: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.
Authors: Allahyari, Abolghasem1 (AUTHOR), Ehsanpour, Ali2 (AUTHOR), Najafi, Behrouz3 (AUTHOR), Ansarinejad, Nafiseh4 (AUTHOR), Mehrzad, Valiollah5 (AUTHOR), Kalantari, Behjat6 (AUTHOR), Raafat, Jahangir7 (AUTHOR), Ghadiany, Mojtaba8 (AUTHOR), Shahi, Farhad9 (AUTHOR), Gharib, Behrooz10 (AUTHOR), Moazed, Vahid11 (AUTHOR), Khosravi, Adnan12 (AUTHOR), Mirpour, Mir Hossein13 (AUTHOR), Salari, Sina14 (AUTHOR), Mortazavizadeh, Seyedmohammadreza15 (AUTHOR), Nekoyi, Amirabbas16 (AUTHOR), Khani, Mohsen17 (AUTHOR), Sadeghi, Alireza18 (AUTHOR), Gharib, Sirus19 (AUTHOR), Bary, Alireza20 (AUTHOR)
Source: BMC Cancer. 12/22/2022, Vol. 22 Issue 1, p1-10. 10p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:14712407
DOI:10.1186/s12885-022-09895-5